ProPhase Labs (NASDAQ:PRPH) Shares Cross Above Two Hundred Day Moving Average of $2.60

Share on StockTwits

ProPhase Labs Inc (NASDAQ:PRPH)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.60 and traded as high as $1.88. ProPhase Labs shares last traded at $2.01, with a volume of 8 shares trading hands.

Separately, TheStreet lowered ProPhase Labs from a “c-” rating to a “d+” rating in a research report on Tuesday, July 9th.

The firm has a 50 day moving average of $1.99 and a 200-day moving average of $2.60.

ProPhase Labs (NASDAQ:PRPH) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.11) earnings per share (EPS) for the quarter. The business had revenue of $1.65 million during the quarter. ProPhase Labs had a negative return on equity of 21.71% and a negative net margin of 35.98%.

An institutional investor recently bought a new position in ProPhase Labs stock. Susquehanna International Group LLP acquired a new stake in ProPhase Labs Inc (NASDAQ:PRPH) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,717 shares of the company’s stock, valued at approximately $29,000. Susquehanna International Group LLP owned approximately 0.12% of ProPhase Labs as of its most recent filing with the SEC. Institutional investors and hedge funds own 4.33% of the company’s stock.

ProPhase Labs Company Profile (NASDAQ:PRPH)

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.

Featured Story: Is it Safe to Invest in Commodities?

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with's FREE daily email newsletter.